GT Biopharma Inc
Change company Symbol lookup
Select an option...
GTBP GT Biopharma Inc
KALA Kala Pharmaceuticals Inc
HTGC Hercules Capital Inc
MPW Medical Properties Trust Inc
ST Sensata Technologies Holding PLC
ZTS Zoetis Inc
AZZ AZZ Inc
CRM Salesforce Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Closing Price
$3.07
Day's Change
0.19 (6.60%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.07
Day's Low
2.77
Volume
(Light)
Volume:
152,951

10-day average volume:
393,307
152,951

Display:

Providers:

UpdateCancel
6 providers
June 16, 2022
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of GT Biopharma, Inc. (GTBP)

NEW YORK, NY / ACCESSWIRE / June 16, 2022 / Levi & Korsinsky announces it has commenced an investigation of GT Biopharma, Inc. (NASDAQ:GTBP) concerning possible breaches of fiduciary duty. To obtain additional information, go to:(Accesswire)

June 14, 2022
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating GT Biopharma, Inc. for Potential Breach of Fiduciary Duty Claims

NEW YORK, NY / ACCESSWIRE / June 14, 2022 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of GT Biopharma, Inc. (NASDAQ:GTBP).(Accesswire)

June 10, 2022
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE(R)) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

EQNX::TICKER_START (NASDAQ:GTBP), EQNX::TICKER_END -- Future studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers GT Biopharma, Inc. ("the Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company...(Globe Newswire)

May 16, 2022
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

EQNX::TICKER_START (NASDAQ:GTBP), EQNX::TICKER_END GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell...(Globe Newswire)

May 12, 2022
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

EQNX::TICKER_START (NASDAQ:GTBP), EQNX::TICKER_END GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE(R)...(Globe Newswire)

April 11, 2022
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE(R) Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo - Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment (Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.